Drugs & Targets Braftovi combination receives approval in China for BRAFV600E-mutant metastatic colorectal cancer July 18, 2025Vol.51 No.28
Drugs & Targets Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing July 11, 2025Vol.51 No.27
Drugs & Targets FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins July 03, 2025Vol.51 No.26
Drugs & Targets FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM July 03, 2025Vol.51 No.26
Drugs & Targets REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated July 03, 2025Vol.51 No.26
Drugs & Targets FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC June 27, 2025Vol.51 No.25
Drugs & Targets FDA grants Breakthrough Therapy designation for daraxonrasib in pancreatic cancer June 27, 2025Vol.51 No.25
Drugs & Targets CHMP adopts positive opinion of Sarclisa + SOC for transplant-eligible newly diagnosed MM June 27, 2025Vol.51 No.25
Drugs & Targets CHMP adopts positive opinion of cabozantinib for previously treated advanced neuroendocrine tumors June 27, 2025Vol.51 No.25
